OncoMatch/Clinical Trials/NCT07256236
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
Is NCT07256236 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Sacituzumab tirumotecan and QL1706 for cervical cancer.
Treatment: Sacituzumab tirumotecan · QL1706 — This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — recurrent or metastatic
Have experienced failure of at least one prior line of platinum-based standard therapy or intolerance to platinum-based drugs in the recurrent or metastatic setting, or have experienced radiologically confirmed disease progression during or within 6 months after completion (≥4 cycles) of platinum-based neoadjuvant or adjuvant chemotherapy.
Cannot have received: TROP2-targeted therapy
Subjects who have previously received TROP2-targeted therapy
Cannot have received: topoisomerase I inhibitor
any drug containing a topoisomerase I inhibitor, including antibody-drug conjugate (ADC) therapy
Cannot have received: experimental anticancer vaccine
any experimental anticancer vaccine
Cannot have received: drug targeting T-cell co-stimulation pathways
any drug targeting T-cell co-stimulation pathways
Lab requirements
Blood counts
Neutrophil count (NEUT#) ≥1.5×10⁹/L; Platelets (PLT) ≥100×10⁹/L; Hemoglobin ≥90 g/L
Kidney function
Creatinine clearance (Ccr) ≥50 ml/min (Cockcroft-Gault); Urine protein ≤1+; if urine protein ≥2+, then 24-hour urine protein quantification must be ≤1.0 g
Liver function
AST and ALT ≤2.5 × ULN; for subjects with baseline liver metastases, ALT and AST ≤5 × ULN; Albumin ≥30 g/L; Total bilirubin (TBIL) ≤1.5 × ULN
Cardiac function
LVEF ≥50%
Adequate organ and bone marrow function ... defined as follows: Neutrophil count (NEUT#) ≥1.5×10⁹/L; Platelets (PLT) ≥100×10⁹/L; Hemoglobin ≥90 g/L; AST and ALT ≤2.5 × ULN; for subjects with baseline liver metastases, ALT and AST ≤5 × ULN; Albumin ≥30 g/L; Total bilirubin (TBIL) ≤1.5 × ULN; Creatinine clearance (Ccr) ≥50 ml/min (Cockcroft-Gault); Urine protein ≤1+; if urine protein ≥2+, then 24-hour urine protein quantification must be ≤1.0 g; INR, APTT, and PT ≤1.5 × ULN; LVEF ≥50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify